Literature DB >> 20877300

Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project.

N Perroud1, R Uher, M Y M Ng, M Guipponi, J Hauser, N Henigsberg, W Maier, O Mors, M Gennarelli, M Rietschel, D Souery, M Z Dernovsek, A S Stamp, M Lathrop, A Farmer, G Breen, K J Aitchison, C M Lewis, I W Craig, P McGuffin.   

Abstract

Suicidal thoughts during antidepressant treatment have been the focus of several candidate gene association studies. The aim of the present genome-wide association study was to identify additional genetic variants involved in increasing suicidal ideation during escitalopram and nortriptyline treatment. A total of 706 adult participants of European ancestry, treated for major depression with escitalopram or nortriptyline over 12 weeks in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study were genotyped with Illumina Human 610-Quad Beadchips (Illumina, San Diego, CA, USA). A total of 244 subjects experienced an increase in suicidal ideation during follow-up. The genetic marker most significantly associated with increasing suicidality (8.28 × 10(-7)) was a single-nucleotide polymorphism (SNP; rs11143230) located 30 kb downstream of a gene encoding guanine deaminase (GDA) on chromosome 9q21.13. Two suggestive drug-specific associations within KCNIP4 (Kv channel-interacting protein 4; chromosome 4p15.31) and near ELP3 (elongation protein 3 homolog; chromosome 8p21.1) were found in subjects treated with escitalopram. Suggestive drug by gene interactions for two SNPs near structural variants on chromosome 4q12, one SNP in the apolipoprotein O (APOO) gene on chromosome Xp22.11 and one on chromosome 11q24.3 were found. The most significant association within a set of 33 candidate genes was in the neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene. Finally, we also found trend for an association within genes previously associated with psychiatric phenotypes indirectly linked to suicidal behavior, that is, GRIP1, NXPH1 and ANK3. The results suggest novel pathways involved in increasing suicidal ideation during antidepressant treatment and should help to target treatment to reduce the risk of this dramatic adverse event. Limited power precludes definitive conclusions and replication in larger sample is warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20877300     DOI: 10.1038/tpj.2010.70

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  37 in total

Review 1.  Suicidal ideation during antidepressant treatment: do genetic predictors exist?

Authors:  Nader Perroud
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 2.  The molecular bases of the suicidal brain.

Authors:  Gustavo Turecki
Journal:  Nat Rev Neurosci       Date:  2014-10-30       Impact factor: 34.870

Review 3.  Neuropathology of suicide: recent findings and future directions.

Authors:  P-E Lutz; N Mechawar; G Turecki
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

Review 4.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 5.  Endophenotypes as a measure of suicidality.

Authors:  Dimitry A Chistiakov; Zurab I Kekelidze; Vladimir P Chekhonin
Journal:  J Appl Genet       Date:  2012-09-02       Impact factor: 3.240

6.  Receptors and other signaling proteins required for serotonin control of locomotion in Caenorhabditis elegans.

Authors:  Güliz Gürel; Megan A Gustafson; Judy S Pepper; H Robert Horvitz; Michael R Koelle
Journal:  Genetics       Date:  2012-09-28       Impact factor: 4.562

7.  Genome-wide association study of antidepressant treatment-emergent suicidal ideation.

Authors:  Andreas Menke; Katharina Domschke; Darina Czamara; Torsten Klengel; Johannes Hennings; Susanne Lucae; Bernhard T Baune; Volker Arolt; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 8.  PharmGKB summary: citalopram pharmacokinetics pathway.

Authors:  Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

9.  Genome-wide association study of the child behavior checklist dysregulation profile.

Authors:  Eric Mick; James McGough; Sandra Loo; Alysa E Doyle; Janet Wozniak; Timothy E Wilens; Susan Smalley; James McCracken; Joseph Biederman; Stephen V Faraone
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-07-13       Impact factor: 8.829

10.  Genomewide association studies of suicide attempts in US soldiers.

Authors:  Murray B Stein; Erin B Ware; Colter Mitchell; Chia-Yen Chen; Susan Borja; Tianxi Cai; Catherine L Dempsey; Carol S Fullerton; Joel Gelernter; Steven G Heeringa; Sonia Jain; Ronald C Kessler; James A Naifeh; Matthew K Nock; Stephan Ripke; Xiaoying Sun; Jean C Beckham; Nathan A Kimbrel; Robert J Ursano; Jordan W Smoller
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-09-13       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.